7/25/2012 7:13:37 AM
ThromboGenics NV (THR) fell as much as 19 percent after the U.S. Food and Drug Administration said it had concerns about the safety of the company’s eye drug. The shares traded 8.8 percent lower at 22.83 euros as of 2:52 p.m in Brussels. The intraday decline is the steepest since June 5. Side effects including eye pain, perceived flashes of light, blurred vision and impaired vision happened two to four times more often in patients receiving ocriplasmin than those getting a placebo in a trial, the FDA said in a staff report today.
comments powered by